Please use this identifier to cite or link to this item:
Title: Routine versus selective cardiac magnetic resonance in non-ischemic heart failure - OUTSMART-HF: Study protocol for a randomized controlled trial (IMAGE-HF (heart failure) project 1-B)
Authors: Paterson, I
Wells, GA
Ezekowitz, JA
White, JA
Friedrich, MG
Mielniczuk, LM
O'Meara, E
Chow, B
deKemp, RA
Klein, R
Dennie, C
Dick, A
Coyle, D
Dwivedi, G
Rajda, M
Wright, GA
Laine, M
Hanninen, H
Larose, E
Connelly, KA
Leong-Poi, H
Howarth, AG
Davies, RA
Duchesne, L
Yla-Herttuala, S
Saraste, A
Farand, P
Garrard, L
Tardif, J-C
Arnold, M
Knuuti, J
Beanlands, R
Chan, KL
Keywords: Cardiac magnetic resonance;Echocardiography;Heart failure;Randomized controlled trial
Issue Date: 2013
Publisher: BioMed Central
Citation: Trials, 14: 332, (2013)
Abstract: Background: Imaging has become a routine part of heart failure (HF) investigation. Echocardiography is a first-line test in HF given its availability and it provides valuable diagnostic and prognostic information. Cardiac magnetic resonance (CMR) is an emerging clinical tool in the management of patients with non-ischemic heart failure. Current ACC/AHA/CCS/ESC guidelines advocate its role in the detection of a variety of cardiomyopathies but there is a paucity of high quality evidence to support these recommendations. The primary objective of this study is to compare the diagnostic yield of routine cardiac magnetic resonance versus standard care (that is, echocardiography with only selective use of CMR) in patients with non-ischemic heart failure. The primary hypothesisis that the routine use of CMR will lead to a more specific diagnostic characterization of the underlying etiology of non-ischemic heart failure. This will lead to a reduction in the non-specific diagnoses of idiopathic dilated cardiomyopathy and HF with preserved ejection fraction.Design: Tertiary care sites in Canada and Finland, with dedicated HF and CMR programs, will randomize consecutive patients with new or deteriorating HF to routine CMR or selective CMR. All patients will undergo a standard clinical echocardiogram and the interpreter will assign the most likely HF etiology. Those undergoing CMR will also have a standard examination and will be assigned a HF etiology based upon the findings. The treating physician's impression about non-ischemic HF etiology will be collected following all baseline testing (including echo ± CMR). Patients will be followed annually for 4 years to ascertain clinical outcomes, quality of life and cost. The expected outcome is that the routine CMR arm will have a significantly higher rate of infiltrative, inflammatory, hypertrophic, ischemic and 'other' cardiomyopathy than the selective CMR group.Discussion: This study will be the first multicenter randomized, controlled trial evaluating the role of CMR in non-ischemic HF. Non-ischemic HF patients will be randomized to routine CMR in order to determine whether there are any gains over management strategies employing selective CMR utilization. The insight gained from this study should improve appropriate CMR use in HF. Trial registration: NCT01281384. © 2013 Paterson et al.; licensee BioMed Central Ltd.
Description: © 2013 Paterson et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
ISSN: 1745-6215
Appears in Collections:Health Economics Research Group (HERG)

Files in This Item:
File Description SizeFormat 
Fulltext.pdf487.25 kBAdobe PDFView/Open

Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.